Shanghai Haohai Biological Technology Co Ltd 2025 AR2
The report outlines Shanghai Haohai Biological Technology Co., Ltd.'s financial and operational performance for the fiscal year 2025. Despite facing temporary declines in key financial indicators due to changes in value-added tax rates and intense market competition in the intraocular lens business, the company made significant progress in its research and development pipeline, with multiple products receiving marketing approvals. The company also maintained stable cash dividends and executed share repurchases of both A shares and H shares. Additionally, the company advanced its corporate governance by transitioning the duties of the supervisory committee to the audit committee.
Company: Shanghai Haohai Biological Technology Co Ltd
Sector: Manufacturing
Country: China
Year: 2025
Type: AR2
Pages: 203
Back to company
Shanghai Haohai Biological Technology Co Ltd
Annual Report
The report outlines Shanghai Haohai Biological Technology Co., Ltd.'s financial and operational performance for the fiscal year 2025. Despite facing temporary declines in key financial indicators due to changes in value-added tax rates and intense market competition in the intraocular lens business, the company made significant progress in its research and development pipeline, with multiple products receiving marketing approvals. The company also maintained stable cash dividends and executed share repurchases of both A shares and H shares. Additionally, the company advanced its corporate governance by transitioning the duties of the supervisory committee to the audit committee.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees